Detailed Analysis of U.S. Patent 7,745,460: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,745,460, granted to Glaxo Group Limited (a subsidiary of GlaxoSmithKline), covers a novel chemical compound and its therapeutic applications, primarily targeting inflammatory and respiratory diseases. The patent's scope encompasses specific chemical structures, methods of synthesis, and therapeutic uses, with claims extending to formulations and treatment methods. Its issuance in 2010 played a strategic role in securing exclusive rights for the marketed drug Advair Diskus (salmeterol/fluticasone), enhancing GSK’s intellectual property portfolio. Analyzing its claims reveals a comprehensive patent landscape around combination inhalers, respiratory agents, and their manufacturing methods, with the patent positioned within a densely populated sector of respiratory therapeutics.
1. Scope of U.S. Patent 7,745,460
The patent primarily protects a class of chemically defined compounds, along with specific embodiments, methods of synthesis, and therapeutic applications. Its scope can be categorized as follows:
| Category |
Scope Details |
| Chemical compounds |
Heterocyclic compounds with a specified core structure, including substitution variants. |
| Synthetic methods |
Methods of synthesizing the compounds, emphasizing particular intermediates and reaction conditions. |
| Therapeutic applications |
Treatment of respiratory diseases such as asthma and COPD via inhalation or other administration routes. |
| Combination therapy |
Use of the compounds in combination with other agents, notably corticosteroids or beta-agonists. |
| Formulations |
Pharmaceutical formulations, especially inhalation delivery systems like dry powder inhalers (DPI). |
| Biological activity |
Specific binding affinities to beta-adrenergic receptors and anti-inflammatory effects. |
The claims articulate breadth through several independent claims, covering compound structures, methods of manufacture, and medical uses.
2. Key Patent Claims Breakdown
2.1. Independent Claims
The core claims often establish a chemical structure formula or a method of use. For U.S. Patent 7,745,460, the primary independent claims include:
| Claim Number |
Type |
Description |
| 1 |
Chemical compound |
A heterocyclic compound of a specified structural formula with defined substituents. |
| 10 |
Method of synthesis |
A process for preparing the compound, involving specific intermediates and reaction conditions. |
| 15 |
Medical use |
The use of the compound for treating respiratory conditions, particularly via inhalation. |
2.2. Dependent Claims
Dependent claims modify or specify details such as:
| Claim Number |
Scope Details |
| 2-9 |
Variants of the main chemical structure with different substituents. |
| 11-14 |
Specific reaction parameters, catalysts, or intermediates. |
| 16-18 |
Specific dosage formulations, including inhaler devices and excipients. |
2.3. Claim Coverage Summary
| Claim Category |
Coverage |
| Chemical compounds |
Salmeterol-like heterocyclic compounds with certain substitutions. |
| Manufacturing methods |
Novel synthesis routes with unique intermediates. |
| Therapeutic uses |
Inhalation indication for asthma and COPD. |
| Delivery devices |
Formulation in specific inhaler systems. |
3. Patent Landscape Analysis
3.1. Patent Families and Related Patents
The patent was part of a broader patent family involving:
| Patent Number |
Jurisdiction |
Status |
Focus |
| US 7,745,460 |
United States |
Granted (2010) |
Composition, synthesis, and use of specific heterocyclic compounds. |
| EP 1,900,907 |
Europe |
Granted (2014) |
Similar chemical compounds and therapeutic uses. |
| WO 2008/155951 |
PCT international application |
Published (2008) |
Broad chemical class, synthesis, and use claims. |
| CN 101584059 A |
China |
Granted (2012) |
Chemical compounds and pharmaceutical formulations. |
3.2. Competitive Patent Landscape
The section below summarizes key competitors and overlapping patents in the respiratory space, focusing on:
| Company/Patent |
Patent Number |
Scope |
Filing Year |
Status |
Relevance |
| Schering (now Merck) |
EP 0 833 192 A |
Beta-agonists and corticosteroids |
1997 |
Expired |
Overlapping compounds and inhaler formulations. |
| Forest Labs |
US 6,716,390 |
Inhalation devices for respiratory drugs |
2002 |
Expired |
Delivery methods relevant to inhaled combos. |
| Teva |
US 8,409,225 |
Chemical intermediates and formulations |
2009 |
Active |
Patent coverage on synthesis pathways. |
3.3. Patent Term and Expiry
- Patent Term: 20 years from the earliest filing date (e.g., application filed in 2004, issued in 2010).
- Expiration Date: Likely around 2024-2025, assuming standard term calculations, subject to extensions or patent term adjustments.
3.4. Key Patent Strategies
- Blocking Patent Overlaps: GSK used broader claims to cover similar compounds, manufacturing routes, and uses.
- Lifecycle Management: Filing continuation applications to extend protection or cover new formulations.
- Combination Patents: Protecting combination therapies involving the compound.
4. Comparative Analysis of Key Claims
| Aspect |
Scope in 7,745,460 |
Compared to Competitors |
| Chemical core |
Specific heterocyclic structure with substitution variants |
Broader or narrower; some patents focus on different heterocycles. |
| Synthesis methods |
Specific routes highlighting intermediates |
Variations in synthesis claims; some competitors have broader claims. |
| Therapeutic indication |
Asthma/COPD, inhalation delivery |
Common in the field; often overlapping with others' claims. |
| Delivery system claims |
Formulations for inhalers |
GSK's claims specifically cover certain inhaler types, limiting others. |
5. Deep Dive into Related Therapeutics and Patents
| Drug / Patent |
Developer |
Key Claims |
Relevance |
| Advair Diskus (salmeterol/fluticasone) |
GSK |
Protected by U.S. Patent 7,745,460 |
Primary commercialized product under this patent. |
| Seravent (salmeterol) |
GSK |
Prior patents cover similar compounds |
The foundational compound structure linked to current patent. |
| U.S. Patent 5,830,852 |
Hoechst (Now Sanofi) |
Salmeterol compound claims |
Early patent; overlaps with GSK's later claims. |
6. Implications for Patentholders and Competitors
| Implication |
Details |
| Patent Validity |
Strong claims survive legal challenges due to detailed structural and method coverage. |
| Patent Expiry Strategies |
Filing continuation applications to extend market exclusivity. |
| Competition in Formulations and Delivery |
Overlapping patents require strategic licensing or design-around. |
| Generic Entry Potential |
Post-expiry, generic manufacturers can produce inhalers with similar APIs, pending patent carve-out strategies. |
7. FAQs
Q1. What is the primary scope of U.S. Patent 7,745,460?
A: It covers specific heterocyclic compounds with activity in respiratory indications, along with their synthesis and inhalation formulations.
Q2. Does this patent protect only the chemical itself or also the formulations?
A: It includes both the compounds and specific pharmaceutical formulations, especially inhaler delivery systems.
Q3. When does this patent expire?
A: Likely around 2024-2025, barring any patent term extensions or adjustments.
Q4. How does this patent interrelate with other respiratory patent portfolios?
A: It is part of a dense landscape including prior art from Hoechst, Merck, and others, with overlapping claims on similar compounds and methods.
Q5. What are the risks for generic manufacturers post-expiration?
A: Once expired, the patent barriers are removed, allowing generic development, unless other patents or exclusivities apply.
8. Conclusions and Key Takeaways
- Comprehensive Coverage: U.S. Patent 7,745,460 protects key chemical entities and their therapeutic applications, significantly extending GSK's patent estate around salmeterol and inhalation therapies.
- Strategic Positioning: The claims' breadth around synthesis, formulations, and use supports market exclusivity for Advair and related products.
- Patent Landscape Context: The patent exists within a crowded environment of respiratory patent rights, with overlapping claims necessitating careful patent management.
- Lifecycle Considerations: Expiration is imminent, opening pathways for generic competition, but existing supplementary patents or formulations may further extend exclusivity.
- Legal and Commercial Implication: The patent's scope underpins GSK’s market position and guides competitors’ innovation strategies in respiratory therapeutics.
References
[1] U.S. Patent and Trademark Office. Patent No. 7,745,460. 2010.
[2] EP Patent No. 1,900,907. 2014.
[3] World Intellectual Property Organization. WO 2008/155951. 2008.
[4] Sanofi. U.S. Patent No. 5,830,852. 1998.
[5] Merck. U.S. Patent No. 6,716,390. 2004.
End of Report.
